These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 10976637)
21. Clinical characteristics of responders to interferon therapy for relapsing MS. Waubant E; Vukusic S; Gignoux L; Dubief FD; Achiti I; Blanc S; Renoux C; Confavreux C Neurology; 2003 Jul; 61(2):184-9. PubMed ID: 12874396 [TBL] [Abstract][Full Text] [Related]
22. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562 [TBL] [Abstract][Full Text] [Related]
23. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis. Trenova AG; Slavov GS; Manova MG; Kostadinova II Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430 [TBL] [Abstract][Full Text] [Related]
24. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders. Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M; J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438 [TBL] [Abstract][Full Text] [Related]
25. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis. McCormack PL; Scott LJ CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221 [TBL] [Abstract][Full Text] [Related]
26. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis. Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628 [TBL] [Abstract][Full Text] [Related]
27. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439 [TBL] [Abstract][Full Text] [Related]
38. Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up. Milosevic E; Dujmovic I; Markovic M; Mesaros S; Rakocevic G; Drulovic J; Mostarica Stojkovic M; Popadic D J Neuroimmunol; 2015 Oct; 287():64-70. PubMed ID: 26439963 [TBL] [Abstract][Full Text] [Related]
39. The clinical impact of interferon beta antibodies in relapsing-remitting MS. Perini P; Calabrese M; Biasi G; Gallo P J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010 [TBL] [Abstract][Full Text] [Related]
40. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]